Table 8Net monetary benefits at £20,000 per QALY gained for different prevalence rates and test accuracy sources for screening people from high prevalence countries

PrevalenceMantoux test/IGTIGTMantoux test
Pai et al. 2008
0.01−34−73Dominated
0.05−32−69Dominated
0.1−30−64Dominated
0.15−28−58Dominated
0.2−26−53Dominated
0.25−24−48Dominated
0.3−22−43Dominated
Diel et al. 2010
0.01−34−74Dominated
0.05−33−69Dominated
0.1−31−64Dominated
0.15−30−60Dominated
0.2−27−53Dominated
0.25Extended Dominated−48Extended Dominated
0.3Extended Dominated−43Extended Dominated

IGT = interferon gamma test. QALY = quality-adjusted life year.

From: 5, Diagnosis

Cover of Tuberculosis
Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control.
NICE Clinical Guidelines, No. 117.
National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK).
Section 5.1, Copyright © 2011, National Institute for Health and Clinical Excellence. Sections 5.2 to 5.4, Copyright © 2006, Royal College of Physicians of London.

For 2006 original guideline text, no part of the content may be reproduced in any form (including photocopying or storing it in any medium by electronic means and whether or not transiently or incidentally to some other issue of this publication) without the written permission of the Royal College of Physicians of London. Applications for the Royal College of Physicians of London's written permission to reproduce any part of this publication should be addressed to the publisher.

For 2011 updated text, the material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.